Maxim Group Thinks Cytori Therap’s Stock is Going to Recover

By Ryan Adsit

Maxim Group analyst Jason Kolbert reiterated a Buy rating on Cytori Therap (NASDAQ: CYTX) today and set a price target of $10. The company’s shares opened today at $0.99, close to its 52-week low of $0.90.

Kolbert commented:

“Cytori announced that all of the 48-week patient follow-ups in the pivotal U.S.”

According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -17.0% and a 29.8% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, ContraVir Pharmaceuticals Inc, and Brainstorm Cell Therapeutics.

Cytori Therap has an analyst consensus of Moderate Buy, with a price target consensus of $10.

The company has a one year high of $3.40 and a one year low of $0.90. Currently, Cytori Therap has an average volume of 720.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cytori Therapeutics, Inc. is a late stage cell therapy company. that engages in the developement of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy acts principally by improving blood flow, modulating the immune system and facilitating wound repair. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.